This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D56.3 | Synonyms: Thalassemia trait, Thalassemia minor, Beta-thalassemia trait, heterozygous thalassemia
The concept of thalassemia began in 1925 when Thomas B. Cooley and P. Lee first described a syndrome of severe anemia and splenomegaly in children of Italian descent. Later, in the 1940s, researchers such as Neel and Valentini described a group of patients with only relatively mild microcytic anemia, namely thalassemia trait (thalassemia minor or thalassemia trait), as an independent clinical category. They observed that mild hematologic abnormalities consistently appeared in the parents of patients with severe thalassemia (thalassemia major).
In 1949, J.V. Neel proposed the hypothesis that thalassemia follows an autosomal recessive mode of inheritance, with homozygotes showing severe disease and heterozygotes showing a mild trait. Subsequently, from the 1950s to the 1970s, researchers such as Ingram, Stretton, Kan, and Weatherall elucidated the molecular basis of the beta-globin gene, establishing that thalassemia trait is caused by a heterozygous variant of the HBB gene.
From the late 1970s, with the introduction of recombinant DNA technology and molecular cloning, a wide variety of beta-globin gene variants (more than 200) causing thalassemia trait were characterized. Once it was established that elevated HbA2 is a reliable indicator of the beta-thalassemia trait, large-scale population screening programs using it were successfully implemented in Mediterranean countries. The programs implemented in Italy, Greece, and Cyprus are regarded as successful models that reduced the birth rate of severe thalassemia by more than 90%.
The cause of thalassemia trait (especially the beta-thalassemia trait) is a heterozygous variant of the HBB (hemoglobin beta) gene located on the short arm of chromosome 11 (11p15.4). More than 200 pathogenic HBB variants are known worldwide, and the variants take various forms, including point variants (missense, nonsense), frameshift variants, splicing variants, and small deletions/insertions.
Beta-globin gene variants are broadly divided into b0 (complete loss of beta chain synthesis) and b+ (reduced beta chain synthesis). In heterozygotes, b0 variants may have somewhat higher HbA2 levels and more severe anemia than b+ variants, but clinically both types are mild. Common variants by major ethnic group: in Mediterranean populations, IVS1.110 G>A, IVS1.1 G>T, and codon 39 C>T; in Southeast Asia, codon 17 and codon 41/42; in people of African descent, IVS2.849 A>G.
Beta-thalassemia is inherited in an autosomal recessive manner. A carrier (heterozygote) of the thalassemia trait has one normal beta-globin gene and one pathogenic variant. A single normal gene alone synthesizes enough beta chains, so clinical symptoms are mild or absent.
| Genotype | Beta chain synthesis | HbA2 | HbF | Clinical phenotype |
|---|---|---|---|---|
| b0 heterozygous | 50% of normal | 4~7% | 1~5% | Thalassemia trait (mild) |
| b+ heterozygous | 60~80% of normal | 3.5~5% | 0.5~3% | Thalassemia trait (mild) |
| b0/b0 homozygous | Absent | Absent | ~100% | Thalassemia major (severe) |
In beta-thalassemia heterozygotes, a coexisting alpha-globin gene deletion (alpha-thalassemia trait) partially relieves the alpha-beta chain imbalance and can lessen the degree of anemia, but HbA2 levels may also decrease somewhat, complicating the diagnosis. In such complex genotypes, molecular genetic analysis is essential.
The beta-thalassemia trait is one of the most common single-gene disorders in the world. About 1.5% of the world population is estimated to be carriers of the beta-thalassemia trait, corresponding to more than 100 million people. Carrier frequency is especially high (10~20% or more) in the Mediterranean coast (Italy, Greece, Cyprus), the Middle East (Iran, Iraq), the Indian subcontinent, Southeast Asia (Thailand, Vietnam), and Africa.
The beta-thalassemia trait is very rare among native Koreans in Korea. However, with the increase in foreign workers and marriage immigrants from Southeast Asia, South Asia, and the Middle East, cases of thalassemia trait carriers are steadily increasing. Cases found during prenatal screening in multicultural families in Korea are increasing, and improvement of the genetic counseling and molecular genetic diagnostic system is needed.
Thalassemia trait is known to confer partial resistance to falciparum malaria (Plasmodium falciparum). This is explained as the evolutionary basis for the maintenance of a high carrier frequency in regions where malaria is endemic.
In thalassemia trait, the pathogenic HBB gene completely or partially reduces beta chain synthesis. However, because one normal HBB allele is present, total beta chain synthesis is maintained at 50~80% of normal. This degree of beta chain reduction does not cause a significant alpha-beta chain imbalance, so only a small amount of alpha chain aggregates form within red blood cells.
The reason HbA2 (alpha2delta2) levels rise in the beta-thalassemia trait is explained by the relative preference for delta chains to combine with alpha chains when beta chain synthesis is reduced. Elevated HbA2 (3.5~7%) is the most reliable diagnostic indicator of the beta-thalassemia trait.
Even a small excess of alpha chains causes some red blood cell membrane damage, which somewhat shortens red blood cell lifespan and produces microcytosis and hypochromia. In the bone marrow, erythropoiesis increases slightly as compensation, but there are almost no clinical symptoms.
Thalassemia trait (beta-thalassemia trait) is mostly without clinical symptoms. Many carriers are discovered incidentally during routine blood tests or prenatal screening. Even when patients complain of symptoms such as fatigue or headache, the degree of anemia (Hb 10~13 g/dL) is often not enough to interfere with most daily activities.
During pregnancy, dilutional anemia from increased plasma volume overlaps with the microcytic anemia of thalassemia trait, and anemia may worsen somewhat. In this case, symptoms such as fatigue and shortness of breath can occur, and anemia may worsen further if folate deficiency coexists.
Because thalassemia trait is a microcytic hypochromic anemia, it is clinically similar to iron deficiency anemia and is often misdiagnosed. Many carriers are misdiagnosed with iron deficiency anemia and commonly take unnecessary iron supplements for a long time, which can lead to iron overload. Accurate differential diagnosis is essential.
Most carriers of thalassemia trait are normal on physical examination. Mild pallor may be observed, but there are no findings such as jaundice, splenomegaly, hepatomegaly, or skeletal deformity.
Complete blood count (CBC): marked microcytic hypochromic anemia with Hb 10~13 g/dL, MCV 55~75 fL, MCH 17~24 pg. The red blood cell (RBC) count is often normal or increased, so the Mentzer index (MCV/RBC) is below 13. HPLC/electrophoresis: HbA2 3.5~7%, HbF 1~5% elevated. Serum ferritin and serum iron normal (in the absence of iron deficiency).
| Test item | Thalassemia trait | Iron deficiency anemia |
|---|---|---|
| MCV/MCH | Markedly decreased | Decreased |
| RDW | Normal to mildly increased | Markedly increased |
| Serum ferritin | Normal | Decreased |
| HbA2 | 3.5% or higher | Normal to mildly decreased |
| Mentzer index | Below 13 | 13 or higher |
| Response to iron therapy | None | Present |
The main purpose of carrier screening for thalassemia trait is to prevent the birth of children with severe thalassemia (thalassemia major). High-risk countries around the world operate systematic screening programs that proceed from first-line screening based on maternal CBC to hemoglobin electrophoresis and molecular testing when abnormalities are found.
The combination of MCV <80 fL and MCH <27 pg is the standard criterion for thalassemia trait screening. However, these criteria alone cannot distinguish it from iron deficiency anemia, so iron deficiency must be excluded with serum ferritin or serum iron/TIBC. Microcytic anemia without iron deficiency strongly suggests thalassemia trait.
HbA2 measurement is central to the diagnosis of the beta-thalassemia trait. HbA2 >= 3.5% is the diagnostic criterion and can be measured accurately by HPLC. When iron deficiency coexists, HbA2 may be measured somewhat low, so retesting after correcting iron deficiency is recommended.
The standard diagnostic method for the beta-thalassemia trait is HbA2 measurement by HPLC or capillary electrophoresis. Beta-thalassemia trait is diagnosed when HbA2 of 3.5% or higher (generally 4~7%) is confirmed. HbF may be mildly elevated (1~5%), which is more common with b0 variants.
Specific variants are identified by allele-specific PCR, reverse dot blot hybridization, or Sanger sequencing of the HBB gene. Molecular diagnosis is essential especially for atypical findings, couple counseling, and prenatal diagnosis. An NGS-based globin gene panel is gradually becoming standard.
Iron deficiency anemia: decreased serum ferritin, increased RDW, normal HbA2, responds to iron therapy. Alpha-thalassemia trait: normal HbA2, decreased MCV/MCH, alpha-globin deletion confirmed by molecular testing. Lead poisoning: elevated blood lead level, basophilic stippling. Sickle cell trait + thalassemia: HbS fraction confirmed on HPLC.
When both partners are carriers of the beta-thalassemia trait, HBB gene analysis is performed on fetal DNA by CVS (10~13 weeks) or amniocentesis (15~20 weeks). Prenatal genetic testing is strongly recommended for couples at risk (25%) of having a child with thalassemia major.
Most carriers of thalassemia trait do not need special treatment. Unnecessary iron supplementation should be avoided because it can instead cause iron overload. In practice, indiscriminate iron administration after misdiagnosing thalassemia trait as iron deficiency anemia is a common problem.
Folic acid supplementation (0.4~1 mg/day) is recommended, and especially during pregnancy, 800 mcg~1 mg/day of folic acid is needed. This is because mild hemolysis persists and folate consumption is increased.
Partner screening and genetic counseling are key components of management. When both partners are thalassemia carriers, sufficient counseling about the risk (25%) of thalassemia major in their children and prenatal diagnosis options (CVS, amniocentesis, PGT-M) should be provided.
The prognosis of carriers of thalassemia trait is very good. They maintain a normal lifespan and quality of life, with no restrictions on daily life, occupation, or sports activities. Serious complications or organ damage do not occur from thalassemia trait itself.
The prognosis in pregnancy is also generally good, but monitoring for possible worsening of anemia during pregnancy is needed. With folic acid supplementation and appropriate prenatal care, most women deliver normally. The need for transfusion is extremely rare unless iron deficiency coexists.
Carriers of thalassemia trait are sometimes misdiagnosed with iron deficiency anemia and take unnecessary iron supplements for a long time, which can lead to iron overload. Accurate diagnosis is important for preventing overtreatment.
The key is not prevention of thalassemia trait itself but prevention of the birth of children with severe thalassemia. In high-risk countries (Italy, Greece, Cyprus, Iran, Thailand, etc.), premarital or pre-pregnancy carrier screening programs have been run successfully and have reduced the birth rate of severe thalassemia by more than 90%.
When both partners are carriers of the thalassemia trait, prenatal genetic testing (CVS or amniocentesis) is used in each pregnancy to determine the fetal genotype, and when an affected fetus is identified, appropriate counseling and decision-making support are provided. Preimplantation genetic testing (PGT-M) is a technical option to prevent implantation of an affected embryo during in vitro fertilization.
With the growth of the multicultural family and immigrant population in Korea, improved access to screening of high-risk pregnant women and to genetic counseling is needed. Building a collaborative system among obstetricians, hematologists, and genetic counselors is required.